Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M
Xilio Therapeutics reported its Q2 2026 financial results, showing $18.7 million in collaboration revenue and a net loss of $6.4 million. The company held $136.0 million in cash and cash equivalents, expecting this to fund operations into Q1 2028. Key business highlights include FDA …